{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.71","value":"69.4"},{"groupId":"OG001","spread":"0.98","value":"63.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"title":"Global Health Status/QoL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.78","value":"83.5"},{"groupId":"OG001","spread":"1.07","value":"77.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"title":"Physical Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.70","value":"82.3"},{"groupId":"OG001","spread":"0.97","value":"76.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"title":"Emotional Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.01","value":"79.0"},{"groupId":"OG001","spread":"1.38","value":"75.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"title":"Social Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.68","value":"86.7"},{"groupId":"OG001","spread":"0.94","value":"84.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"title":"Cognitive Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.03","value":"79.5"},{"groupId":"OG001","spread":"1.44","value":"71.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"title":"Role Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.84","value":"25.9"},{"groupId":"OG001","spread":"1.17","value":"31.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"title":"Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.58","value":"11.8"},{"groupId":"OG001","spread":"0.82","value":"11.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"title":"Nausea and Vomiting"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.75","value":"14.7"},{"groupId":"OG001","spread":"1.05","value":"16.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"title":"Pain"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.75","value":"15.0"},{"groupId":"OG001","spread":"1.05","value":"22.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"title":"Dyspnea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.78","value":"14.8"},{"groupId":"OG001","spread":"1.09","value":"21.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"title":"Insomnia"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.82","value":"15.9"},{"groupId":"OG001","spread":"1.15","value":"19.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"title":"Appetite Loss"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.60","value":"8.1"},{"groupId":"OG001","spread":"0.84","value":"13.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"title":"Constipation"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.80","value":"25.7"},{"groupId":"OG001","spread":"1.12","value":"4.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"title":"Diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.19","value":"19.9"},{"groupId":"OG001","spread":"1.63","value":"23.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"160"}],"units":"Participants"}],"title":"Financial Difficulties"}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"description":"The EORTC QLQ-C30 contained 30 items and was of both multi-item scales and single-item measures, including 5 functional scales (physical, role, emotional, cognitive, and social functioning), 3 symptom scales (fatigue, nausea/vomiting, and pain), 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties), and a global health status (GHS)/quality of life (QoL) scale. Items were assessed on a 4- or 7-level Likert scale, ranging from 1=\"very poor\" to 7= \"excellent\" for GHS items and 1= \"not at all\" to 4= \"very much\" for all other items. The scores of the scales were averaged from the scores of the component items, transformed, and analyzed on a 0 - 100 scale. A high score represented a higher response level. The scores were analyzed using repeated measurement model for longitudinal data, including terms for visit, treatment, treatment by time interaction, strata and baseline score. Overall mean and standard error were obtained","dispersionType":"Standard Error","groups":[{"description":"Ceritinib administered continuously through oral dosing at a dosage of 750 mg once daily in fasted state","id":"OG000","title":"Ceritinib"},{"description":"Pemetrexed plus cisplatin or carboplatin (based on Investigator's choice) for 4 cycles (Induction) followed by pemetrexed as single agent (Maintenance)","id":"OG001","title":"Chemotherapy"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The Full Analysis Set (FAS) consisted of all patients to whom study treatment had been assigned by randomization. Participants with a baseline assessment for at least one of the scales/single items","reportingStatus":"POSTED","timeFrame":"Screening, treatment phase (Cycles 2, 3 then every 2nd cycle until Month 33; after Month 33, every 9 or 12 weeks, end of treatment); follow-up phase (Every 6 weeks until Month 33; after Month 33 every 9 or 12 weeks) up to approximately 120 months","title":"Least Squares Mean Scores on the EORTC-QLQ C30","type":"SECONDARY","unitOfMeasure":"Score on a scale"}